J&J's plaque psoriasis drug Icotyde drew 18,000+ prescriptions for 11,000 patients in its first full quarter of sales.
July 15, 2026 10:35 AM EDT
J&J's 'must-win launch' Icotyde nabs 18,000 prescriptions in first full quarter
Max Gelman
Johnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter.
Without disclosing …
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to…
AbbVie's Skyrizi maintains momentum despite J&J's Icotyde competition. Q2 Skyrizi sales hit $5.5B as the company raises full-year…
J&J's Imaavy approved for warm autoimmune hemolytic anemia; Takeda's Orzeyful & Rhythm's Imcivree approved in Japan; Basking's…
Strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its…
Johnson & Johnson also increased its full-year sales and profit forecast.
Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker
